Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
More good news in the horizon for people with acromegaly
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it's important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
Same Tumor, Scarier Name: What the PitNET Reclassification Means for You
This is my conversation with Dr. Ken Ho, Professor at St. Vincent's Hospital, Sydney and Garvan Institute of Medical Research, Sydney, Australia, on why a single word could change how pituitary patients are treated, and why leading endocrinologists are asking the WHO (World Health Organization) to reconsider.
Worth noting:
Crinetics Pharmaceuticals, launches a new resource, Everyday Advocacy, with leading patient groups. Read more
From Debiopharm, read about Oxtend™ 3 clinical trial for acromegaly for a long term (3-month) octreotide treatment. More information here.
From Camurus more information on a new treatment option for acromegaly. Read more here
From Crinetics Pharmaceuticals, FDA approves Crinetics PALSONIFY™ for adults with acromegaly . Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
New support site from Chiesi; Rethink acromegaly
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
In this episode, Dr. Mario Maldonado from Recordati Rare Diseases discusses recent advances in endocrinology, focusing on hypercortisolism, diagnostic challenges, and innovative treatments. He shares insights from clinical studies and the future of AI in disease management.
Our live talk sessions of the pituitary and adrenal podcasts continue with this extremely informational conversation on hypothalamic obesity. If you are interested in learning more about his devastating disorder, please listen to Dr. Blevins as he shares his insights and extensive expertise on its causes, new treatments, and latest developments.
Apple Podcasts
Spotify
Amazon Music
Google Podcasts
